Screening of Glaucoma or Cataract Prevalence in Vitiligo Patients and Its Relationship With Periorbital Steroid Use

Khurrum, Huma; AlGhamdi, Khalid M.; Osman, Essam

doi:10.1177/1203475415615325

Cited by 13 publications

(33 citation statements)

References 15 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The coexistence of vitiligo and ocular abnormalities has been explored by several studies. 2,[50][51][52][53] Melanocytes are, in addition to the skin, abundant in the uveal tract (choroid, ciliary body, and iris) and the retinal pigment epithelium (RPE). 50 of glaucoma in a study with larger sample size (90 vitiligo patients) and examined its association with topical use of periorbital corticosteroids.…”

Section: Ocular and Audiological Abnormalities In Patients With Vitiligomentioning

confidence: 99%

“…They found no significant difference in the prevalence of glaucoma or cataracts between cases and controls, even with the use of topical corticosteroids periorbitally. 53 The association between vitiligo and audiological abnormalities are highlighted in the literature. 2,28,[54][55][56] Melanocytes are also distributed in the membranous labyrinth of the inner ear with the heaviest pigmentation in scala vestibuli.…”

Section: Ocular and Audiological Abnormalities In Patients With Vitiligomentioning

confidence: 99%

See 1 more Smart Citation

Comorbidities in vitiligo: comprehensive review

2018

View full text Add to dashboard Cite

Vitiligo is a common skin disorder characterized by idiopathic, progressive cutaneous hypomelanosis. Vitiligo is associated with several comorbid autoimmune, systemic, and dermatological diseases, primarily thyroid disease, alopecia areata, diabetes mellitus, pernicious anemia, systemic lupus erythematosus, rheumatoid arthritis, Addison's disease, inflammatory bowel disease, Sjögren's syndrome, dermatomyositis, scleroderma, ocular and audiological abnormalities, psoriasis, and atopic dermatitis. It is essential to increase awareness of these comorbidities in order to improve the disease burden and quality of life of patients with vitiligo. Herein, we review the association with the most frequent comorbidities associated with vitiligo.

show abstract

Section: Ocular and Audiological Abnormalities In Patients With Vitiligomentioning

confidence: 99%

Section: Ocular and Audiological Abnormalities In Patients With Vitiligomentioning

confidence: 99%

Comorbidities in vitiligo: comprehensive review

2018

View full text Add to dashboard Cite

show abstract

“…Topical corticosteroids are the mainstay of treatment for localized disease and have been shown to have a reservoir effect that lasts for around 5 days. The risk of development of glaucoma or cataracts in patients using periorbital topical corticosteroids was not found to be raised in case-control studies [ 31 ]. Topical vitamin D analogues have been used with variable outcomes in vitiligo, and the plausible mechanism of action includes immunomodulatory and melanocyte stimulating activities.…”

Section: Stabilization Treatmentsmentioning

confidence: 99%

Clinical and Molecular Aspects of Vitiligo Treatments

Bishnoi

Parsad

2018

IJMS

View full text Add to dashboard Cite

Vitiligo is an asymptomatic but cosmetically disfiguring disorder that results in the formation of depigmented patches on skin and/or mucosae. Vitiligo can be segmental or non-segmental depending upon the morphology of the clinical involvement. It can also be classified as progressing or stable based on the activity of the disease. Further, the extent of involvement can be limited (localized disease) or extensive (generalized disease). The treatment of vitiligo therefore depends on the clinical classification/characteristics of the disease and usually comprises of 2 strategies. The first involves arresting the progression of active disease (to provide stability) in order to limit the area involved by depigmentation. The second strategy aims at repigmentation of the depigmented area. It is also important to maintain the disease in a stable phase and to prevent relapse. Accordingly, a holistic treatment approach for vitiligo should be individualistic and should take care of all these considerations. In this review, we shall discuss the vitiligo treatments and their important clinical and molecular aspects.

show abstract

“…Similar lesions have been described in the literature, with reported rates of 4.5% and 6.5% in the studied vitiligo samples. 10,25 None of our patients had evidence of choroidal nevi in their fundus examination. Reports on choroidal nevi in vitiligo patients have varied, with some studies on black populations reporting 0% incidence in the studied sample 24 and others reporting up to 40% in a Jewish population.…”

Section: Discussionmentioning

confidence: 79%

<p>Assessment of the Effect of Vitiligo on Subfoveal Choroidal Thickness Using Spectral-Domain Optical Coherence Tomography</p>

Fouad

Salman

Mohamed

et al. 2020

OPTH

View full text Add to dashboard Cite

Background: Vitiligo is a common skin condition affecting 0.5-2% of the population. The exact etiology of the condition is unknown, but the result is autoimmune destruction of melanocytes. The eye is rich in melanocytes, especially in the retinal pigment epithelium and choroid. Little is known about the effect of vitiligo on the choroid of the eye. Methods: We cross-sectionally examined 31 right eyes of 31 vitiligo patients and 32 right eyes of 32 age-and sex-matched controls for signs of vitiligo affection and then measured the subfoveal choroidal thickness (SFCT) using spectral-domain optical coherence tomography. Results: There was a statistically significant difference between SFCT in the cases group and the control group (Mean ± SD: 251.9 ± 42.0 μm and 296.8 ± 46.4 μm, respectively, p = 0.0002). The thickness correlated negatively with age (r = −0.5) but did not correlate significantly with disease severity or duration (r = −0.201, −0.1781, p = 0.2783, 0.3381, respectively). Additional examination findings included iris and fundus hypopigmented spots, and peripapillary atrophy. Conclusion: SFCT is reduced among patients with vitiligo. The clinical implications of such a finding should be studied further, and eye screening programs should be considered.

show abstract

Screening of Glaucoma or Cataract Prevalence in Vitiligo Patients and Its Relationship With Periorbital Steroid Use

Abstract: The study suggests that patients who have vitiligo and use topical steroids periorbitally do not have an increased risk of glaucoma or cataracts. Future studies that have a larger sample size and use a detailed steroid use protocol are needed.

Cited by 13 publications

References 15 publications

Comorbidities in vitiligo: comprehensive review

Comorbidities in vitiligo: comprehensive review

Clinical and Molecular Aspects of Vitiligo Treatments

<p>Assessment of the Effect of Vitiligo on Subfoveal Choroidal Thickness Using Spectral-Domain Optical Coherence Tomography</p>

Contact Info

Product

Resources

About